Poppe H, Femmer K, Kaverina N V, Lyskovzev V V, Grigoreva J K, Mazievskij D D
Pharmazie. 1985 Dec;40(12):857-61.
The haemodynamic and cardiac effects of GS 015, a substance of the series of the novel 5-(dialkyl-aminoacyl)-3-carbalkoxyamino-10,11-dihydro-5H-dibenz-[b ,f]-azepines with very potent antifibrillatory and antiarrhythmic actions, are studied on anaesthetized dogs and cats by means of the catheter technique. The clinical symptoms and the therapeutic range were tested on conscious animals. On the strength of the present results it can be stated that GS 015, given at pharmacodynamically effective doses, does not cause any circulatory side effects. A negative inotropic effect appears only at increased doses. Like other antiarrhythmic drugs, GS 015 possesses a limited therapeutic range which should be taken into consideration particularly in case of cardiac insufficiency. But an application seems possible also in patients during the acute stage of myocardial infarction.
GS 015是新型5-(二烷基氨基酰基)-3-烷氧羰基氨基-10,11-二氢-5H-二苯并[b,f]氮杂卓系列中的一种物质,具有非常强的抗纤颤和抗心律失常作用。通过导管技术,在麻醉的狗和猫身上研究了GS 015的血流动力学和心脏效应。在清醒动物身上测试了临床症状和治疗范围。根据目前的结果可以说,以药效学有效剂量给药的GS 015不会引起任何循环系统副作用。仅在剂量增加时才会出现负性肌力作用。与其他抗心律失常药物一样,GS 015的治疗范围有限,在心脏功能不全的情况下尤其应予以考虑。但在心肌梗死急性期的患者中似乎也可以应用。